Wearable remote monitoring for pediatric heart failure patients

There's No Place Like Home…Feasibility of Remote Physiological Monitoring in Childhood Heart Failure

Observational University of Alberta · NCT06969560

This study is testing a new wearable device that helps track the health of kids with heart failure to see if it can improve their care at home and reduce hospital visits.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages8 Years to 18 Years
SexAll
SponsorUniversity of Alberta Academic / other
Drugs / interventionschemotherapy
Locations4 sites (Edmonton, Alberta and 3 other locations)
Trial IDNCT06969560 on ClinicalTrials.gov

What this trial studies

This study focuses on the use of wearable remote physiologic monitoring (RPM) technology to track the health of pediatric patients with heart failure or those at risk of developing it. By enrolling 100 outpatients aged 8-18 from four tertiary pediatric heart failure centers in Canada, the study aims to utilize a Bluetooth-enabled textile device to monitor vital signs such as heart rate, respiratory rate, and blood pressure. The goal is to improve home-based care and reduce reliance on hospital visits, particularly for vulnerable populations. The study will also explore the integration of machine learning algorithms to predict health deterioration based on collected data.

Who should consider this trial

Good fit: Ideal candidates are pediatric outpatients aged 8-18 with or at risk of deteriorating heart failure.

Not a fit: Patients who are not outpatients or do not meet the specified age and health criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide safer, more equitable home-based care for children with heart failure.

How similar studies have performed: While RPM has been successful in adult populations, this approach is novel and untested in pediatric heart failure care.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients from 8-18 years of age who are outpatients at time of study enrollment.
* Patients with a chest size of at least 69.85 cm in perimeter/circumference (as measured under the pectoral muscles)
* Patients at-risk for heart failure and with American Heart Association (AHA) Stage B-D Heart Failure will be included in this study irrespective of heart failure medication use.
* HF etiologies include: congenital cardiac malformation with systemic ventricular systolic dysfunction, idiopathic cardiomyopathy, familial/inherited and/or genetic cardiomyopathy, history of myocarditis with persistent ventricular dysfunction, neuromuscular disorder, inborn error of metabolism, mitochondrial disorder, acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional), ischemic (e.g., Kawasaki disease and post-operative HF), and left ventricular non-compaction, restrictive cardiomyopathy and HCM with systolic or diastolic dysfunction.

Exclusion Criteria:

* Patients within 3 months of a surgery.
* Patients supported by ventricular assist device at study onset.
* Inability to use technology due to physical or cognitive impairment in the patient or caregiver.
* Non-English speaking.
* Patients who have an implantable cardiac defibrillator or pacemaker
* Patients whose chest size is too large or small to fit available sizes of the Skiin device.

Where this trial is running

Edmonton, Alberta and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Heart Failureremote physiologic monitoringheart failureat-risktelemonitoring technologypediatric
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.